NCT04910126

Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Doxorubicin（A）Plus Camrelizumab(C) Versus Doxorubicin Alone for the First-line Treatment(T) of Select Type of Adcanced Soft Tissue Sarcoma(ACTS): a Randomised Controlled Multi Centers Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of the combination of adriamycin and Camrelizumab in the first-line treatment of advanced soft tissue sarcoma

Conditions

• Soft Tissue Sarcoma
• Neoplasms, Connective and Soft Tissue
• Sarcoma Metastatic
• Sarcoma,Soft Tissue

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab 200mg q3w up to 2 years
DRUG	Adriamycin	adriamycin 20mg/m2 d1-3 q3w maximum 6 cycles

Timeline

• Start date: 2020-11-12
• Primary completion: 2023-01-12
• Completion: 2023-11-12
• First posted: 2021-06-02
• Last updated: 2021-06-02

Locations

1 site across 1 country: China